Medication-Related Osteonecrosis of the Jaw Around Dental Implants

Giovannacci, Ilaria; Meleti, Marco; Manfrēdi, M.; Mortellaro, Carmen; Lucchina, A Greco; Bonanini, Mauro; Vescovi, Paolo

doi:10.1097/scs.0000000000002564

Cited by 62 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, surgical intervention per se should not be overemphasized as the main risk factor for MRONJ development. Similarly, it has been suggested that infection around the implants (peri-implantitis) represents a notable risk factor for MRONJ development (Giovannacci et al, 2016;Troeltzsch et al, 2016). This is also in line with the high success rate after surgery on the jawbone to cure MRONJ lesions (see later).…”

Section: Controver S Ie S On Ris K Fac Tor Smentioning

confidence: 54%

Workshop of European task force on medication‐related osteonecrosis of the jaw—Current challenges

et al. 2019

View full text Add to dashboard Cite

Section: Controver S Ie S On Ris K Fac Tor Smentioning

confidence: 54%

Workshop of European task force on medication‐related osteonecrosis of the jaw—Current challenges

et al. 2019

View full text Add to dashboard Cite

“…tailed single-patient data on ARD type and indication for intake, as well as the duration of intake until MRONJ, were possible to extract from four studies (68 patients)(Giovannacci et al, 2016;Holzinger et al, 2014;Jacobsen et al, 2013;Kwon et al, 2014;Lazarovici et al, 2010;Pogrel & Ruggiero, 2017;Troeltzsch et al, 2016).…”

mentioning

confidence: 99%

The effect of antiresorptive drugs on implant therapy: Systematic review and meta‐analysis

Stavropoulos

Bertl

Pietschmann

et al. 2018

Clinical Oral Implants Res

View full text Add to dashboard Cite

Objectives: A considerable portion of the adult population has received and/or is receiving treatment with antiresorptive drugs (ARDs). It is thus relevant to assess possible side effects of ARD intake in connection to various aspects of implant therapy. The aim of this study was to answer the focused question "In patients with systemic intake of ARDs, what is the outcome and complication rate of implant therapy including associated bone grafting procedures comparing to patients without systemic intake of ARDs?" Materials and Methods:Original studies fulfilled predefined inclusion criteria (e.g., case series, cohort studies, case-control studies, and controlled and/or randomized controlled clinical trials; retro-or prospective design; and ≥10 patients with systemic intake of ARDs). Various patient-, medication-, and intervention-related parameters [i.e., implant loss, grafting procedure complication/failure, peri-implant marginal bone levels/loss, medication-related osteonecrosis of the jaws (MRONJ), and periimplantitis] were extracted, and meta-analyses and quality assessment were performed. Results:Twenty-four studies with bisphosphonate (BP) intake (mainly low dose for osteoporosis treatment) and seven studies on hormone replacement therapy (HRT), including ≥10 patients, and controls not taking the medication were identified.Furthermore, seven studies on MRONJ associated with implants were included.Meta-analyses based on four studies reporting on patient level and eight studies reporting on implant level showed no significant differences in terms of implant loss between patients on BPs (mainly low dose for osteoporosis treatment) and controls.Furthermore, low-dose BP intake did not compromise peri-implant marginal bone levels. Based on two studies, no negative effect of HRT was observed on the implant level, while HRT appeared to exert a marginally significant negative effect regarding implant survival on the patient level and regarding peri-implant marginal bone levels.Based on six studies reporting single-patient data, MRONJ in patients on BP for osteoporosis appeared in 70% of the cases >36 months after start of drug intake, while in patients with cancer, MRONJ appeared in 64% of the cases ≤36 months after first BP intake.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | 55STAVROPOULOS eT AL. | 57 STAVROPOULOS eT AL.Random-effects meta-analyses, separately for each ARD type, were implemented to calculate from the included cohort and casecontrol studies pooled estimates at the patient and/or implant level.All statistical analyses were performed using Stata (StataCorp LLC, USA).

show abstract

“…До настоящего времени почти все сообщения об остеонекрозе на фоне терапии бисфосфонатами касались челюстей и были связаны с такими факторами риска, как тип препарата, способ его введения и длительность курса [2,3,4]. При всей актуальности этой проблемы механизм развития осложнений терапии БФ еще недостаточно изучен, но есть основания предполагать, что ключевыми условиями для развития остеонекроза являются травма кости (например, удаление зубов, оперативное вмешательство на пародонте или имплантация), присоединение инфекционного процесса, воспалительные заболевания в полости рта [5,6,7].…”

Section: патоморфологическая характеристика состояния тканей пародонтunclassified

Pathomorphological status of periodontal tissues during bisphosphona tetherapy (experimental research)

Atrushkevich¹,

Berchenko²,

Орехова³

et al. 2019

Medical news of the North Caucasus

View full text Add to dashboard Cite

show abstract

Medication-Related Osteonecrosis of the Jaw Around Dental Implants

Cited by 62 publications

References 21 publications

Workshop of European task force on medication‐related osteonecrosis of the jaw—Current challenges

Workshop of European task force on medication‐related osteonecrosis of the jaw—Current challenges

The effect of antiresorptive drugs on implant therapy: Systematic review and meta‐analysis

Pathomorphological status of periodontal tissues during bisphosphona tetherapy (experimental research)

Contact Info

Product

Resources

About